share_log

Alzamend Neuro And 3 Other Stocks Under $3 Insiders Are Buying

Alzamend Neuro And 3 Other Stocks Under $3 Insiders Are Buying

Alzamend Neuro和其他3只低於3美元的股票內部人士正在買入
Benzinga ·  01/10 21:09

$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
The Dow Jones index closed lower by over 150 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

150 萬美元押注這隻醫療保健股？看看內部人士正在積極買入的這4只細價股
道瓊斯指數週二收盤下跌超過150點。當內部人士購買或出售股票時，這表明他們對公司前景的信心或擔憂。對細價股感興趣的投資者和交易者可以將此視爲他們整體投資或交易決策的一個因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是細價股最近幾筆值得注意的內幕交易。欲了解更多信息，請查看 本辛加的內幕交易 平台。

Fortress Biotech

堡壘生物科技

  • The Trade: Fortress Biotech, Inc. (NASDAQ:FBIO) President, CEO and Chairman MD Lindsay Rosenwald acquired a total of 50,000 shares an average price of $2.38. To acquire these shares, it cost around $118,770.
  • What's Happening: Fortress Biotech recently announced pricing of an $11 million registered direct offering priced at-the-market under Nasdaq rules.
  • What Fortress Biotech Does: Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products.
  • 交易：Fortress Biotech, Inc.（納斯達克股票代碼：FBIO）總裁、首席執行官兼董事長林賽·羅森瓦爾德 共收購了5萬股股票 平均價格爲2.38美元。收購這些股票的成本約爲118,770美元。
  • 發生了什麼：豐澤生物科技最近宣佈了根據納斯達克規則在市場上定價的1100萬美元註冊直接發行的定價。
  • 豐澤生物科技的所作所爲：豐澤生物科技公司是一家生物製藥公司。該公司參與藥品和生物技術產品的收購、開發和商業化業務。

Alzamend Neuro

Alzamend Neuro

  • The Trade: Alzamend Neuro, Inc. (NASDAQ:ALZN) 10% owner Milton C. Ault III acquired a total of 5,000 shares at at an average price of $1.02. To acquire these shares, it cost around $5,093.
  • What's Happening: Alzamend Neuro recently received a "Study May Proceed" letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD).
  • What Alzamend Neuro Does: Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments.
  • 交易：Alzamend Neuro, Inc.（納斯達克股票代碼：ALZN）10% 的所有者 Milton C. Ault III 共收購了 5,000 股股票 平均價格爲1.02美元。收購這些股票的成本約爲5,093美元。
  • 發生了什麼：Alzamend Neuro最近收到了美國食品藥品管理局的 “研究可能繼續” 的信，要求啓動研究 AL001-PTSD01，這是一項針對創傷後應激障礙（PTSD）的 AL001 的2A期研究。
  • Alzamend Neuro做什麼：Alzamend Neuro Inc是一家處於早期臨床階段的生物製藥公司。它專注於開發用於治療神經退行性疾病和精神疾病（包括阿爾茨海默氏症）的新產品。其使命是開發和銷售安全有效的治療方法。

Check This Out: KB Home, PriceSmart And 3 Stocks To Watch Heading Into Wednesday

看看這個： 進入週三，KB Home、PriceSmart和3只值得關注的股票

Nemaura Medical

Nemaura Medical

  • The Trade: Nemaura Medical Inc. (OTC:NMRD) Chief Operating Officer Arash Ghadar acquired a total of 100,000 shares at an average price of $0.14. The insider spent around $14,000 to buy those shares.
  • What's Happening: The company's stock fell around 40% over the past month.
  • What Nemaura Medical Does: Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading.
  • 貿易：Nemaura Medical Inc.（場外交易代碼：NMRD）首席運營官阿拉什·加達爾 共收購了10萬股股票 平均價格爲0.14美元。知情人士花費了大約14,000美元購買了這些股票。
  • 發生了什麼：該公司的股票在過去一個月中下跌了約40％。
  • Nemaura Medical的所作所爲：Nemaura Medical Inc是一家醫療技術公司，開發SugarBeat是一種非侵入性、經濟實惠且靈活的連續血糖監測儀（CGM），專爲糖尿病患者和糖尿病前期患者設計以管理其血糖水平。使用指尖的葡萄糖讀數進行校準後，胰島素使用者可以輔助使用SugarBeat。

Vivani Medical

維瓦尼醫療

  • The Trade: Vivani Medical, Inc. (NASDAQ:VANI) Director Gregg Williams acquired a total of 6,731 shares at an average price of $1.08. The insider spent around $7,269 to buy those shares.
  • What's Happening: Vivani Medical, during November, posted a wider-than-expected quarterly loss.
  • What Vivani Medical Does: Vivani Medical Inc is a preclinical stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases.
  • 交易：Vivani Medical, Inc.（納斯達克股票代碼：VANI）董事格雷格·威廉姆斯 共收購了6,731股股票 平均價格爲1.08美元。知情人士花費了約7,269美元購買了這些股票。
  • 發生了什麼：Vivani Medical在11月公佈的季度虧損超出預期。
  • Vivani Medical做什麼：Vivani Medical Inc是一家臨床前階段的生物製藥公司。它利用其專有的 NanoPortal 技術開發微型皮下植入物，從而能夠長期、接近恒定速率地輸送各種治療慢性病的藥物。


Don't forget to check out our premarket coverage here


別忘了在這裏查看我們的上市前報道

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論